Applied DNA Sciences introduces SigNature DNA in new pharmaceutical-grade and packaging inks
SigNature DNA offers authenticity and traceability for pharmaceutical global supply chains.
Applied DNA Sciences has introduced its SigNature DNA marker into new pharmaceutical-grade and packaging inks suitable for tablet and packaging marking, in partnership with Nissha Printing Company and Kishu Giken Kogyo.
Powered by unique botanical-based SigNature DNA, these inks allow for seamless marking at the point-of-manufacture, ensuring that original raw materials or ingredients used to produce pharmaceuticals are fully protected and traceable to point-of-sale. APDN has completed trials with Nissha and KGK partners, proving that unique SigNature DNA marks can be authenticated on the pharmaceutical tablet and packaging materials. The technology satisfies the principles established by FDA Guidelines for inclusion in pharmaceutics and is equally applicable to food and cosmetic products.
APDN can also DNA-mark other elements of a finished product including bulk APIs, cellulosic excipients (bulk fillers) that are used in almost all drug tablets and the commercial binders and enteric coatings that hold prescription and OTC drug tablets together. This unique, multi-factor identification enables verification of its authenticity at any point in the supply chain. Countries around the world have accelerated their adoption of drug quality regulations in the effort to ensure product integrity and protect patient safety. Regulations covering more than 75% of the global medicine supply by 2018 include packaging standards from Japan's Ministry of Health, Labor and Welfare and directives from the FDA's Title II of the Drug Supply Chain Security Act. Companies acting now can benefit from SigNature DNA solutions that forensically backstop pharmaceutical traceability.
"The scalability of SigNature DNA for pharmaceuticals solves many supply chain challenges as recently highlighted in Scientific American. Many of our clients that are using SigNature DNA know that forensic tagging and authentication will protect them from the risk of legal liability and product recall while maintaining profitability and market differentiation," stated Dr James A. Hayward, President and CEO, APDN.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.